Altamira Therapeutics Stock Today
| CYTO Stock | USD 0.44 0 0.45% |
Performance0 of 100
| Odds Of DistressLess than 32
|
Altamira Therapeutics is selling at 0.438 as of the 22nd of November 2024; that is 0.45 percent decrease since the beginning of the trading day. The stock's open price was 0.44. Altamira Therapeutics has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Altamira Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of August 2014 | Category Healthcare | Classification Health Care |
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. Altamira Therapeutics is traded on NASDAQ Exchange in the United States. The company has 3.78 M outstanding shares of which 31.09 K shares are currently shorted by private and institutional investors with about 0.6 trading days to cover. More on Altamira Therapeutics
Moving together with Altamira Stock
| 0.81 | VRAX | Virax Biolabs Group | PairCorr |
| 0.61 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.75 | DYN | Dyne Therapeutics | PairCorr |
| 0.81 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Altamira Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Altamira Stock Highlights
| President, Founder | Thomas Meyer | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAltamira Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Altamira Therapeutics' financial leverage. It provides some insight into what part of Altamira Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Altamira Therapeutics (CYTO) is traded on NASDAQ Exchange in USA. It is located in Clarendon House, Hamilton, Bermuda, HM 11 and employs 10 people. Altamira Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.66 M. Altamira Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.78 M outstanding shares of which 31.09 K shares are currently shorted by private and institutional investors with about 0.6 trading days to cover.
Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Altamira Therapeutics Probability Of Bankruptcy
Ownership AllocationAlmost 96.35 percent of Altamira Therapeutics outstanding shares are held by general public with 0.52 (percent) owned by insiders and only 3.13 % by other corporate entities.
Check Altamira Ownership Details
Altamira Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.9 K | |
| Ubs Group Ag | 2024-06-30 | 1.7 K | |
| Group One Trading, Lp | 2024-06-30 | 14.0 | |
| Lri Investments, Llc | 2024-06-30 | 1.0 | |
| Tower Research Capital Llc | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 |
Altamira Therapeutics Historical Income Statement
Altamira Stock Against Markets
Altamira Therapeutics Corporate Management
| Covadonga Paeda | Chief Officer | Profile | |
| Covadonga Paneda | Chief Officer | Profile | |
| Jean Lechance | Unit Bus | Profile | |
| Samuel MD | Chief Officer | Profile | |
| Marcel CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.94 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.